GlassScriptPhysician profile
Noelle E Miller
NPI 1508968546
$4,341.01
in general payments reported to CMS, 2019-2025
35 companies · $773 in 2025
The $773 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $326 · 2021: $689 · 2022: $769 · 2023: $607 · 2024: $775 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,154.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $508.72 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Glaxosmithkline, LLC. | $457.67 | 2019-2025 | Bexsero, Penmenvy |
| Corium, LLC | $426.00 | 2021-2025 | Azstarys |
| Tris Pharma INC | $391.08 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $281.18 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $279.52 | 2019-2024 | Jornay Pm |
| Genentech USA, INC. | $163.94 | 2019-2022 | |
| Kaleo, INC. | $155.13 | 2021-2023 | Auvi-Q |
| Pfizer INC. | $141.81 | 2022-2024 | |
| Acadia Pharmaceuticals INC | $139.60 | 2024-2025 | Daybue |
| Collegium Pharmaceutical, INC. | $139.11 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $133.24 | 2020-2025 | Doc Band |
| Vertical Pharmaceuticals, LLC | $130.55 | 2024-2025 | Relexxii |
| Sanofi Pasteur INC. | $125.41 | 2019-2023 | |
| Sobi, INC | $123.51 | 2019-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $82.41 | 2022-2024 | Flumist Quadrivalent |
| Ultragenyx Pharmaceutical INC. | $82.11 | 2020-2023 | |
| Avion Pharmaceuticals | $75.05 | 2023 | Methylphenidate Hydrochloride |
| Neos Therapeutics, LP | $62.58 | 2019-2024 | Cotempla Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $59.34 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $52.49 | 2019 | |
| Adlon Therapeutics L.P. | $36.48 | 2020-2021 | |
| Modernatx, INC. | $33.80 | 2025 | Spikevax |
| Seqirus USA INC | $30.72 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Shire North American Group INC | $28.27 | 2019 | |
| Biomarin Pharmaceutical INC. | $27.49 | 2023 | Voxzogo 1.2mg |
| Mayne Pharma Commercial LLC | $26.07 | 2023 | |
| Nestle Healthcare Nutrition INC. | $23.44 | 2023 | |
| Biogen, INC. | $21.88 | 2024 | Spinraza |
| Abbott Laboratories | $18.59 | 2025 | Id Now Instrument |
| Sanofi-Aventis U.S. LLC | $17.91 | 2024 | |
| Phadia US INC. | $17.50 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.25 | 2025 | Koselugo |
| Ars Pharmaceuticals Operations, INC. | $16.87 | 2025 | Neffy |
| Mission Pharmacal Company | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noelle Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.